ViiV's Dovato: Treatment-Naive HIV Is Earmarked For The "Complete Regimen"
Executive Summary
The first approval in the US of a once-daily single-tablet, two-drug regimen for treatment-naive HIV from the HIV/AIDS therapy specialist, ViiV Healthcare, suggests a shift away from three-drug regimens for HIV/AIDS could be gathering pace.
You may also be interested in...
ViiV Looks Ahead With Third-Gen Integrase Inhibitor From Shionogi
License deal for preclinical S-365598 continues longstanding R&D relationship between ViiV and stakeholder Shionogi, which also developed dolutegravir and cabotegravir.
A Rocky First Quarter For Big Pharma Stocks
Big pharma stocks, with few exceptions, saw big declines in valuation in the quarter amid the COVID-19 stock market rollercoaster, but pharma outperformed the S&P 500, showing the industry's resiliency in a global health crisis.
GSK Gets A Boost From Shingrix And Other New Drugs
The shingles vaccine Shingrix and new HIV and respiratory drugs drove first quarter growth at GlaxoSmithKline, even as Advair and Breo sales were impacted by a generic.